NCT04728893

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2021-04-05Est. Completion: 2029-01-04

Enrollment target: 490 participants

Locations

Highlands Oncology Group ( Site 2728), Springdale, Arkansas, United States
University of California San Diego Moores Cancer Center ( Site 2717), La Jolla, California, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724), Torrance, California, United States
Colorado Blood Cancer Institute ( Site 2726), Denver, Colorado, United States
The University of Louisville, James Graham Brown Cancer Center ( Site 2729), Louisville, Kentucky, United States
Mayo Clinic - Rochester ( Site 2706), Rochester, Minnesota, United States
Astera Cancer Care ( Site 2732), East Brunswick, New Jersey, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704), Hackensack, New Jersey, United States
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708), Fargo, North Dakota, United States
UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas, Texas, United States
Medical Oncology Associates (Summit Cancer Centers) ( Site 2710), Spokane, Washington, United States
Hospital Aleman ( Site 0102), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…

Los Angeles, United StatesEst. completion Mar 31, 2029

Breast CancerBreast CarcinomaCancer of the BreastMalignant Neoplasm of Breast

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.